Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

BACKGROUND: The single-arm, phase II Tasigna Efficacy in Advanced Melanoma (TEAM) trial evaluated the KIT-selective tyrosine kinase inhibitor nilotinib in patients with KIT-mutated advanced melanoma without prior KIT inhibitor treatment. PATIENTS AND METHODS: Forty-two patients with KIT-mutated adva...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, J., Carvajal, R. D., Dummer, R., Hauschild, A., Daud, A., Bastian, B. C., Markovic, S. N., Queirolo, P., Arance, A., Berking, C., Camargo, V., Herchenhorn, D., Petrella, T. M., Schadendorf, D., Sharfman, W., Testori, A., Novick, S., Hertle, S., Nourry, C., Chen, Q., Hodi, F. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452069/
https://www.ncbi.nlm.nih.gov/pubmed/28327988
http://dx.doi.org/10.1093/annonc/mdx079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452069/
https://www.ncbi.nlm.nih.gov/pubmed/28327988
http://dx.doi.org/10.1093/annonc/mdx079

Ejemplares similares